^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiKa (camrelizumab)

    i
    Other names: INCSHR-1210, SHR1210, HR301210, HR 301210, INCSHR 1210, SHR 1210, INCSHR1210, SHR-1210, HR-301210
    Company:
    CG Invites, HLB Bio Group, Jiangsu Hengrui Pharma, NPO Petrovax
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC (clinicaltrials.gov)
    P3, N=262, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N=192 --> 262 | Trial completion date: Jul 2027 --> Jul 2029 | Trial primary completion date: Jul 2026 --> Jul 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    3d
    Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer (clinicaltrials.gov)
    P2, N=39, Recruiting, Women's Hospital School Of Medicine Zhejiang University | Not yet recruiting --> Recruiting | Trial completion date: Dec 2029 --> Dec 2031 | Trial primary completion date: Sep 2029 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • AiRuiKa (camrelizumab)
    8d
    A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov)
    P2/3, N=737, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2/3 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Enshuxing (enlonstobart) • SYS6010
    8d
    Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial (clinicaltrials.gov)
    P2, N=0, Withdrawn, Women's Hospital School Of Medicine Zhejiang University | N=59 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    AiRuiKa (camrelizumab)
    13d
    PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT (clinicaltrials.gov)
    P=N/A, N=43, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    AiRuiKa (camrelizumab) • azacitidine
    14d
    Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment (clinicaltrials.gov)
    P2, N=30, Recruiting, Sun Yat-sen University
    New P2 trial • Checkpoint inhibition
    |
    AiRuiKa (camrelizumab) • AiRuiKang (dalpiciclib)
    15d
    Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. (clinicaltrials.gov)
    P1/2, N=25, Active, not recruiting, Fujian Medical University Union Hospital | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Nov 2026
    Enrollment closed • Trial completion date
    |
    AiRuiKa (camrelizumab)
    15d
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC (clinicaltrials.gov)
    P3, N=260, Recruiting, Sun Yat-sen University
    New P3 trial • Head-to-Head
    |
    cisplatin • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    15d
    Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    17d
    A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation (clinicaltrials.gov)
    P2, N=251, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    22d
    Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer. (PubMed, J Transl Med)
    A combination of vemurafenib, cetuximab combined with camrelizumab exhibited manageable adverse reactions and efficacy in BRAF V600E-mutated/MSS patients with metastatic colorectal cancer who progressed after standard treatment. This is a pilot study and a larger phase II trials is planned to validate the findings. (ClinicalTrials.gov ID: NCT05019534).
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Zelboraf (vemurafenib) • AiRuiKa (camrelizumab)
    1m
    Myocarditis and Myasthenia Gravis Induced by Camrelizumab in a Patient With Metastatic B2 Thymoma: A Case Report. (PubMed, Thorac Cancer)
    He received chemotherapy plus anlotinib for four cycles since May 5, 2023, and underwent radiotherapy from May 23, 2023 to June 30, 2023. Finally, the patient was discharged after treatment with glucocorticoids, immunoglobulin, and pyridostigmine. Although immune checkpoint inhibitors have achieved similar anti-tumor effects in thymomas as in other solid tumors, they may be closely associated with serious immune-related adverse events, so special caution is required when using immune checkpoint inhibitors in thymoma patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • NPPB (Natriuretic Peptide B)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Focus V (anlotinib) • AiRuiKa (camrelizumab)